Semax Research Review: BDNF, Dopamine, and Neuroprotection Studies

Last updated: May 2026

Semax is a synthetic heptapeptide derived from the ACTH(4-10) chain with a Pro-Gly-Pro tail added to the C-terminus. ACTH(4-10) is a fragment of ACTH hormone (ACTH). It retains receptor-binding action without the full hormone’s adrenal boost. Semax was developed in Russia in the 1980s. It aimed to study  effects of ACTH fragments in the absence of cortisol signaling. According to a review in the Journal of Molecule Brain science (2012). Semax raised brain-derived neurotrophic factor (BDNF). Its receptor TrkB in rodent models. Suggesting a pathway for the brain-protect effects found in lab stroke models.

Next Level Pharm supplies research-grade Semax tested to at least 99 percent purity by HPLC. Mass spec on every batch. A Certificate of Test with a lot of ships with every order.

The sections below cover Semax structure, receptor drug action, BDNF. Dopamine research, brain-protect study findings, and what experts should check before sourcing.

Key Takeaways

1. What it is: Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from ACTH(4-10) with a C-end Pro-Gly-Pro tail. It holds the compound in nasal mucosa studies.
2. BDNF: Many rodent model studies link Semax to increased BDNF output in cortex. Hippocampus, which experts study in brain-protect and neuroplasticity contexts.
3. Dopamine research: Studies report that Semax modulates dopaminergic. Serotonergic action in rodent models, effects experts study in attention and mood-linked brain research.
4. Brain-protect: Published animal studies report reduced infarct volume. Improved brain-related scores in lab stroke models treated with Semax compared to controls.
5. Sourcing standard: Research-grade Semax needs HPLC purity above 99 percent, mass spec type check. A lot-exact COA for traceable lab use.

Here is a closer look at the Semax pathway, neurotrophic. Brain signal research, and what experts should check before sourcing.

What Is Semax and How Was It Derived?

Semax was developed at the Institute of Molecular Genetics of the Russian School of Sciences in the late 1980s. Experts sought to study the CNS-active fragment of ACTH without triggering adrenal cortisol output. Native ACTH causes. The core chain Met-Glu-His-Phe corresponds to ACTH positions 4 through 7. The fragment driving for CNS receptor link. Positions 8, 9, and 10 of ACTH were replaced with Pro-Gly-Pro, a C-end tail. It slows enzyme breakdown in nasal mucosa.

This design allowed experts to study ACTH receptor action in brain tissue using intranasal use without systemic ACTH side effects. The molecule weight of about 900 daltons keeps Semax in the group of small peptides. It can penetrate the smell pathway. According to a structural and pharmacological review in Neuroscience. Biobehavioral Reviews (2009), the Pro-Gly-Pro tail was the key change. It extended the compound’s research value beyond earlier ACTH fragment analogs.

How Does Semax Interact With Brain Receptors?

Semax’s primary research-grade action involves pigment signal receptors (MC1R through MC5R), mainly MC4R. MC3R, which are expressed in brain regions including the hippocampus, cortex, and brain base. These receptors mediate ACTH’s central effects separate from adrenal signaling. Semax’s ACTH-derived chain binds these receptors with binding similar to the parent fragment.

Beyond pigment signal receptor link, studies in rodent models report downstream effects on BDNF, dopamine. Serotonin pathways. These downstream effects are the primary focus of Semax research since they may explain the behavior. Brain-protect findings in animal studies. The receptor link starts a signaling cascade that modulates neurotrophin gene action in a pattern. Its experts have defined it in many cortical and hippocampal assays. According to a receptor pharmacology study in Peptides (2007). MC4R trigger was found as the primary upstream event in Semax-induced BDNF rise in cortical tissue.

Browse brain peptides at Next Level Pharm for COA-tested Semax and linked brain peptide research compounds.

What Does BDNF Research Show for Semax?

Brain-derived neurotrophic factor (BDNF) is a neurotrophin. It supports neuronal survival, synaptic change, and learning and memory storage in rodent models. Reduced BDNF levels are found in animal models of stroke, depression, and brain-damaging terms. Compounds that raise BDNF are studied as potential brain-protect research tools.

According to a study in the Journal of Molecular Neuroscience (2012). A single intranasal use of Semax increased BDNF mRNA. Protein levels in rat cortex and hippocampus within six hours. TrkB, the primary BDNF receptor, showed parallel rise. The study reported that BDNF increases were largest in cortical regions. Persisted for up to 24 hours in a level-dependent pattern. These findings have been repeated in similar cortical tissue studies testing ACTH fragment analogs. Neurotrophin responses.

What Does Dopamine and Serotonin Research Show for Semax?

Dopaminergic and serotonergic systems control attention, drive, and mood-linked brain states in animal models. Semax research has examined its effects on both systems in rodent models. Studies using brain sampling and receptor link assays report changes in dopamine. Serotonin turnover in frontal cortex and striatal regions following Semax use.

According to a neurochemistry study in Neuropeptides (2006), Semax increased dopamine. Serotonin turnover in rat frontal cortex compared to vehicle controls. The changes were found at levels. It also produced BDNF rise, suggesting a aligned brain chemical response pattern. Experts use these findings to design study protocols testing Semax’s value as a brain chemical control tool in attention. Cognition model studies.

What Do Experimental Stroke Studies Show for Semax?

Lab ischemic stroke models in rodents produce defined brain infarct volumes. It experts use to test brain-protect compound effects. Smaller infarct volumes. Better brain-related recovery scores in treated animals indicate a brain-protect effect due to the compound being studied.

According to a study in Stroke (2001), Semax-treated rats showed greatly smaller infarct volumes. Improved brain-related function scores at 24 and 72 hours post-low blood flow compared to saline controls. The study proposed BDNF rise as the pathway since BDNF has established brain-protect effects in low blood flow models. These findings established Semax as an active research tool in lab stroke brain-protect studies. Led to its authorized trial-based study in Russia.

What Quality Standards Apply to Research-Grade Semax?

Research-grade Semax needs HPLC purity above 99 percent to ensure. It the heptapeptide chain is the dominant compound in the sample. Since Semax is studied in sensitive brain chemical assays where small amounts of flaws could affect BDNF assay readings or receptor link data. Purity check is directly relevant to data quality.

Mass spec confirms the exact molecule weight of the Met-Glu-His-Phe-Pro-Gly-Pro chain with the Pro-Gly-Pro tail. Both the core ACTH-derived residues and the C-end tail need to be present. Correctly formed for the compound to have the receptor link profile described in published research. A lot-exact COA with both lab results provides the sourcing records needed for replicable lab research.

Frequently Asked Questions

What is Semax peptide?

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-10) fragment with a C-end Pro-Gly-Pro tail. It was developed to study CNS pigment signal receptor effects without adrenal boost. Research-grade Semax is used in lab models of brain-protect, BDNF signaling, and brain chemical control.

How does Semax work in brain research models?

Semax binds pigment signal receptors (MC3R and MC4R) in the brain. The MC4R trigger starts a signaling cascade that raises BDNF. TrkB output in cortical and hippocampal tissue in rodent models. Secondary effects on dopaminergic. Serotonergic turnover in the frontal cortex have also been reported in brain chemical assay studies.

What does research show about Semax and BDNF?

According to a 2012 study in the Journal of Molecule Brain science, Semax increased BDNF mRNA. Protein in rat cortex and hippocampus within six hours of intranasal use. TrkB receptor output increased in parallel. The increases were level-dependent and persisted for up to 24 hours in the brain regions studied.

Has Semax been studied in stroke models?

Yes. A 2001 study in Stroke reported that Semax-treated rats showed smaller infarct volumes. Improved brain-related function scores at 24 and 72 hours after lab low blood flow. The authors proposed BDNF rise as the brain-protect pathway. Semax has been studied in authorized trial-based settings in Russia based on these lab findings.

Does Semax affect dopamine levels in research models?

Published rodent studies report that Semax increases dopamine. Serotonin turnover in frontal cortex and striatal regions. A 2006 study in Brain peptide found these changes at levels that also produced BDNF rise. Experts use these findings in study designs testing Semax as a brain chemical control tool in attention. Cognition models.

What purity standard applies to research-grade Semax?

Research-grade Semax needs HPLC purity above 99 percent. Mass spec proof of the heptapeptide molecule weight, including the Pro-Gly-Pro C-end tail. Both the core ACTH-derived chain. The C-end tail must be intact for the compound to have the receptor link profile described in published research. A lot-exact COA records both results.

Is Semax for human use?

The research-grade compound is for lab research only. It is not approved for human use, therapeutic, or diagnostic purposes in the United States. All published studies cited in this article used rodent models or controlled early-phase research protocols. The compound should not be given to humans outside of a licensed trial-based trial with appropriate control approval.

Where does Semax ship from?

Research-grade Semax ships to all 50 states within the United States. A Certificate of Test with HPLC purity data, mass spec results. Lot number ships with every order to support full sourcing records for lab research.

Summary

Semax is a synthetic heptapeptide derived from ACTH(4-10) with a brain-protect-oriented research history. Published animal studies link it to BDNF and TrkB rise in cortex and hippocampus, dopaminergic. Serotonergic control in frontal cortex, and reduced infarct volumes in lab stroke models. The pathway involves pigment signal receptor triggers, mainly MC4R, upstream of BDNF pathway changes. Research-grade sourcing needs HPLC purity above 99 percent, mass spec check, and a lot-exact COA.

What Should You Do Next?

Browse research-grade Semax at Next Level Pharm for COA-tested options with full HPLC. Mass spec data on every batch.

People Also Read

• Selank Research: GABA Pathways, Mechanisms, and Study Findings
• KPV Peptide Research: Anti-Inflammatory Mechanisms and Study Overview

About the Author

Next Level Pharm Research Team

Alex M covers peer-reviewed findings in peptide science for Next Level Pharm, a US-based supplier of research-grade peptides verified to >=99% purity via HPLC and mass spectrometry on every batch.

Disclaimer: The information provided on this page is for educational and research purposes only. Next Level Pharm’s products are intended for laboratory research use only. They are not intended for human consumption, diagnostic, therapeutic, or medicinal purposes. This content does not constitute medical advice. Always consult a licensed healthcare professional before making any health-related decisions.